Ozempic & GLP-1 Lawsuit
semaglutide / tirzepatide · Novo Nordisk · Eli Lilly · updated June 2026
Also covers Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda lawsuit claims.
GLP-1 drugs such as Ozempic and Wegovy face thousands of lawsuits alleging severe gastrointestinal injury (gastroparesis, intestinal blockage) and, in a separate federal case, permanent vision loss (NAION).
This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Ozempic caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.
What the lawsuits allege
Plaintiffs allege the manufacturers failed to adequately warn that GLP-1 receptor agonists can cause severe, sometimes long-lasting gastrointestinal injury and, in separate claims, non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, permanent vision loss.
- Gastroparesis (stomach paralysis)
- Ileus / intestinal blockage
- NAION vision loss
FDA action
In September 2023 the FDA added “ileus” (intestinal blockage) to the Ozempic prescribing information.
Verify against the current FDA-approved label: Ozempic label on DailyMed (U.S. NLM).
Where the litigation stands
As of mid-2026, roughly 3,900 lawsuits are consolidated across two federal MDLs: about 3,760 gastrointestinal-injury claims in MDL 3094 (Eastern District of Pennsylvania) plus roughly 110–150 NAION vision-loss claims in the newer MDL 3163. Bellwether (test) trial selection is expected in late 2026–2027.
Case counts and MDL status are published by the U.S. Judicial Panel on Multidistrict Litigation — JPML pending MDLs. Any figure not on the court record is attributed to the secondary legal-press links below.
Who may be affected
The Ozempic lawsuits are brought by people who say they used Ozempic (semaglutide / tirzepatide) and were later diagnosed with one or more of the alleged injuries above. Whether any individual situation could support a claim depends on the specific facts, the medical records, and each state's filing deadline (statute of limitations) — which can expire, so timing matters. Only a licensed attorney can evaluate a specific case. This page is general information, not legal advice.
Frequently asked
- What is the Ozempic lawsuit about?
- Plaintiffs allege the manufacturers failed to adequately warn that GLP-1 receptor agonists can cause severe, sometimes long-lasting gastrointestinal injury and, in separate claims, non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, permanent vision loss. As of mid-2026, roughly 3,900 lawsuits are consolidated across two federal MDLs: about 3,760 gastrointestinal-injury claims in MDL 3094 (Eastern District of Pennsylvania) plus roughly 110–150 NAION vision-loss claims in the newer MDL 3163. Bellwether (test) trial selection is expected in late 2026–2027.
- What injuries are alleged in the Ozempic lawsuits?
- Lawsuits allege gastroparesis (stomach paralysis), ileus / intestinal blockage, naion vision loss. These are allegations; a court has not found that Ozempic causes them.
- Has the FDA acted on Ozempic?
- In September 2023 the FDA added “ileus” (intestinal blockage) to the Ozempic prescribing information.
- Is there a deadline to file a Ozempic lawsuit?
- Yes — every state sets a filing deadline (statute of limitations) for product-injury claims, often running from the date of injury or diagnosis, and once it passes a claim is usually barred. The exact window varies by state and circumstances, so anyone considering a claim should check with a licensed attorney promptly. This is general information, not legal advice.